Scarica l'app Stockscreener
11.71
6.65%
0.73
Pre-mercato:
11.53
-0.18
-1.54%
Precedente Chiudi:
$10.98
Aprire:
$11.015
Volume 24 ore:
2.46M
Relative Volume:
1.36
Capitalizzazione di mercato:
$1.50B
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-40.38
EPS:
-0.29
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
-6.47%
1M Prestazione:
-13.07%
6M Prestazione:
+96.81%
1 anno Prestazione:
+187.71%
Intervallo 1D:
$10.94
$11.75
Intervallo di 1 settimana:
$10.58
$12.60
Portata 52W:
$3.4715
$14.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Confronta TRVI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
11.71 | 1.41B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
TRVI Stock Falls -15% With A 7-day Losing Spree On Technical Breakdown - Trefis
Will Trevi Therapeutics Inc. stock rally after Fed decisions2026 world cup usa national team qualification young talents transition play match prediction tactical review - ulpravda.ru
Published on: 2026-01-03 15:10:39 - moha.gov.vn
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 6.3%Here's Why - MarketBeat
Quarterly Recap: What dividend safety score for Trevi Therapeutics Inc stockStock Surge & AI Optimized Trading Strategy Guides - moha.gov.vn
Published on: 2025-12-31 06:38:59 - moha.gov.vn
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - MSN
Trevi Therapeutics (TRVI) targets next phase of growth with leadership change - MSN
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change - Finviz
Flputnam Investment Management Co. Raises Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Is Trevi Therapeutics Inc. stock cheap at current valuationJuly 2025 PreEarnings & High Yield Equity Trading Tips - Улправда
Stifel Maintains Trevi Therapeutics (TRVI) Buy Recommendation - Nasdaq
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - MSN
Trevi Therapeutics stock price target raised to $18 by Stifel on cough drug potential - Investing.com Canada
First Week of TRVI February 2026 Options Trading - Nasdaq
TRVI: Stifel Raises Price Target and Maintains Buy Rating | TRVI Stock News - GuruFocus
What dividend safety score for Trevi Therapeutics Inc. stockJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - DonanımHaber
Why Trevi Therapeutics Inc. stock remains on buy listsJuly 2025 Chart Watch & Comprehensive Market Scan Reports - DonanımHaber
Can Trevi Therapeutics Inc. stock sustain market leadershipWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics Earnings Notes - Trefis
Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria
Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% HigherTime to Buy? - MarketBeat
Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC - MarketBeat
226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat
Trevi Therapeutics appoints new CFO - MSN
Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail
Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria
Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com
Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com
New Haven biotech names new CFO - Hartford Business Journal
Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC - MarketBeat
Trevi Therapeutics appoints David Hastings as new CFO By Investing.com - Investing.com Nigeria
Trevi Therapeutics Taps David Hastings as CFO - Contract Pharma
Trevi Therapeutics appoints David Hastings as new CFO - Investing.com India
Trevi Therapeutics Appoints David Hastings as Chief Financial Officer - citybiz
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Panagora Asset Management Inc. - MarketBeat
Trevi Therapeutics Names David Hastings CFO - marketscreener.com
Trevi Therapeutics announces appointment of David Hastings as chief financial officer - marketscreener.com
Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer - TradingView — Track All Markets
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - cnhinews.com
Trevi Therapeutics edges higher amid takeover speculation - MSN
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):